SCHEMBL138245

SCHEMBL138245

O=Cc1cc(C(F)(F)F)ccc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.39
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
MAPT P10636 2/20 0.37
XBP1 P17861 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PRKDC P78527 1/20 0.37
POLB P06746 2/20 0.36
CES2 O00748 2/20 0.36
KIF11 P52732 1/20 0.36
SIRT1 Q96EB6 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1B1 Q16678 1/20 0.35
AR P10275 1/20 0.34
ERN1 O75460 2/20 0.34
PTPN5 P54829 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL153259 0.84 BACE1 (0.42) TAS2R14ALOX5APFEN1MAPTPRKDC
SCHEMBL7857228 0.81 THRB (0.43) MAPTPOLBKIF11
SCHEMBL6853258 0.81 POLB (0.42) ALOX5APFEN1MAPTPOLBCES2
SCHEMBL30989568 0.80 PRKDC (0.41) MAPTNPSR1PRKDCLMNASMN1; SMN2
SCHEMBL16950904 0.80 TAS2R14 (0.36) TAS2R14MAPTXBP1NPSR1CES2
SCHEMBL23802024 0.80 PRKDC (0.41) MAPTNPSR1PRKDCLMNASMN1; SMN2
SCHEMBL16957940 0.80 PTGS1 (0.39) TAS2R14MAPTXBP1NPSR1CES2
SCHEMBL269221 0.78 BACE1 (0.47) ALOX5APFEN1MAPTPOLBCES2
SCHEMBL663646 0.78 CES2 (0.50) ALOX5APFEN1MAPTPOLBCES2
SCHEMBL4779383 0.76 ALDH1A1 (0.46) ALOX5APFEN1MAPTPOLBCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110372722-B Method for synthesizing sulfur-nitrogen-containing bis-heterocyclic compound 河南师范大学 2020-08-11 CN claimed
EP-4720055-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2026-04-08 EP disclosed
US-12569489-B2 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase ASTRAZENECA AB (SE) 2026-03-10 US disclosed
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
US-20250326777-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) 2025-10-23 US disclosed
EP-4605374-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF Hepaitech (Beijing) Biopharma Technology Co., Ltd. (CN) 2025-08-27 EP disclosed
US-12398089-B2 Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) 2025-08-26 US disclosed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
WO-2025119326-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2025-06-12 WO disclosed
CN-120129676-A Compounds, compositions, and methods thereof 海湃泰克(北京)生物医药科技有限公司 2025-06-10 CN disclosed
US-4874792-A RESPIRATORY SYSTEM DISORDERS SMITHKLINE BECKMAN CORPORATION (US) 1989-10-17 US disclosed
US-4871771-A PHENYL SUBSTITUTED-DITHIA-ALKANEDIOIC ACIDS SMITHKLINE BECKMAN CORPORATION (US) 1989-10-03 US disclosed
EP-0327306-A2 Leukotriene B4 antagonists SMITHKLINE BEECHAM CORPORATION (US) 1989-08-09 EP disclosed
US-4855320-A ANTICONVULSANTS, ANTIEPILEPTICS DR. WILLMAR SCHWABE GMBH & COMPANY (DE) 1989-08-08 US disclosed
US-4820719-A ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS SMITHKLINE BECKMAN CORPORATION (US) 1989-04-11 US disclosed
US-4730005-A DITHIA-ALKANEDIOIC ACIDS SMITHKLINE BECKMAN CORPORATION (US) 1988-03-08 US disclosed
EP-0247320-A2 5-Arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and process for their preparation as well as their application as therapeutically active ingredients Dr. Willmar Schwabe GmbH & Co. (DE) 1987-12-02 EP disclosed
EP-0168902-B1 LEUKOTRIENE ANTAGONISTS SMITHKLINE BECKMAN CORPORATION (US) 1987-09-30 EP disclosed
EP-0202759-A2 Leukotriene antagonists SMITHKLINE BEECHAM CORPORATION (US) 1986-11-26 EP disclosed
EP-0168902-A1 Leukotriene antagonists SMITHKLINE BECKMAN CORPORATION (US) 1986-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398089-B2 Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand POF1B, ADH1C, OSBP TAS2R14 2584/4885ALOX5AP 471/4885FEN1 1354/4885
US-20250326777-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF MRGPRX4, MRGPRX1, MRGPRX2 TAS2R14 3892/4885ALOX5AP 1064/4885FEN1 3910/4885
US-12569489-B2 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase MPO, EPX, LPO TAS2R14 3795/4885ALOX5AP 221/4885FEN1 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.